Noticeably, the CSF of MS patients contains elevated, neurotoxic levels of granzyme B and IL1B and the expression of granzyme B in peripheral CD8+ T cells of SPMS patients positively correlates with the progression of clinical symptoms [106,107]. Here, GZMB is linked to secondary progressive multiple sclerosis.